FENNEC PHARMACEUTICALS INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- FENNEC PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.96M, a 954.30% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $1.32M, a 256.60% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $1.43M, a 809.55% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $186.00K, a 46.40% decline year-over-year.
- FENNEC PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for fiscal 2025 was $2.19M, a 68.33% increase from fiscal 2024.
- FENNEC PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for fiscal 2024 was $1.30M, a 24.18% decline from fiscal 2023.
- FENNEC PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for fiscal 2023 was $1.72M, a 9.02% increase from fiscal 2022.
- FENNEC PHARMACEUTICALS INC. stock issued during period, value, stock options exercised for fiscal 2022 was $1.57M, a 4669.70% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.96M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $1.32M 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $2.19M 10-K · filed 2026-03-27 | |
| 2025-09-30 | $1.43M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $186.00K 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $371.00K 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $1.30M 10-K · filed 2026-03-27 | |
| 2024-09-30 | $157.00K 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $347.00K 10-Q · filed 2025-11-13 | |
| 2024-03-31 | $627.00K 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $1.72M 10-K · filed 2025-03-26 | |
| 2023-09-30 | $215.00K 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $541.00K 10-Q · filed 2024-11-08 | |
| 2023-03-31 | $213.00K 10-Q · filed 2024-11-08 | |
| 2022-12-31 | $1.57M 10-K · filed 2024-03-29 | |
| 2022-09-30 | $188.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $46.00K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $15.00K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $33.00K 10-K · filed 2023-03-29 | |
| 2021-06-30 | $23.00K 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $462.00K 10-K · filed 2022-02-28 | |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-16 | |
| 2018-12-31 | $210.00K 10-K · filed 2020-02-14 | |
| 2018-09-30 | $139.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $35.00K 10-Q · filed 2019-11-12 | |
| 2018-03-31 | $36.00K 10-Q · filed 2019-11-12 | |
| 2017-12-31 | $563.00K 10-K · filed 2019-03-15 | |
| 2017-09-30 | $383.00K 10-Q · filed 2017-11-13 | |
| 2017-06-30 | $98.00K 10-Q · filed 2017-11-13 | |
| 2016-12-31 | $6.00K 10-K · filed 2018-03-28 | |
| 2016-06-30 | $6.00K 10-Q · filed 2017-05-12 | |
| 2015-12-31 | $48.00K 10-K · filed 2017-03-29 | |
| 2015-09-30 | $21.00K 10-Q · filed 2016-11-14 | |
| 2015-03-31 | $27.00K 10-Q · filed 2016-11-14 | |
| 2014-12-31 | $140.00K 10-K · filed 2016-03-28 | |
| 2014-06-30 | $87.00K 10-Q · filed 2014-11-13 | |
| 2014-03-31 | $53.00K 10-Q · filed 2014-11-13 | |
| 2005-12-31 | $25.00K 10-Q · filed 2014-11-13 | |
| 2004-06-30 | $23.00K 10-Q · filed 2014-11-13 | |
| 2003-06-30 | $4.00K 10-Q · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |